Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada
June 07 2022 - 7:30AM
Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX:
TLRY), a leading global cannabis and consumer packaged goods
company inspiring and empowering the worldwide community to live
their very best life, today announced that its medical cannabis
brand, Aphria, has launched CBN Night Oil, the brand’s first CBN
oil medical product formulated for patients’ nighttime use.
Blair MacNeil, President, Tilray Canada, said,
"Tilray Medical is committed to providing patients in Canada and
around the globe with safe, high-quality cannabinoid-based
medicine. We are pleased to add a dedicated night oil to the Aphria
medical portfolio and broaden our offering of effective medical
cannabis products to patients with a wider range of needs.”
CBN, or cannabinol, is derived from THC and is
known to help improve the duration and quality of sleep.1 Aphria’s
CBN-dominant oil is carefully formulated with 30mg CBN per mL and
10mg THC per mL (in a 50mL bottle) and is composed of
broad-spectrum cannabis distillate. Designed to be used in
conjunction with a nighttime routine, Aphria’s CBN Night Oil is now
available across Canada on www.TilrayMedical.ca
About Tilray Medical Tilray
Medical is dedicated to transforming lives and fostering dignity
for patients in need through safe and reliable access to a global
portfolio of medical cannabis brands, including Tilray, Aphria,
Broken Coast, and Symbios. Tilray grew from being one of the first
companies to become an approved licensed producer of medical
cannabis in Canada to building the first GMP-certified cannabis
production facilities in Europe, first in Portugal and later in
Germany. Today, Tilray Medical is one of the biggest suppliers of
medical cannabis brands to patients, physicians, hospitals,
pharmacies, researchers, and governments, in 20 countries and
across five continents.
About Tilray BrandsTilray
Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global
cannabis-lifestyle and consumer packaged goods company with
operations in Canada, the United States, Europe, Australia, and
Latin America that is changing people’s lives for the better – one
person at a time – by inspiring and empowering the worldwide
community to live their very best life by providing them with
products that meet the needs of their mind, body, and soul and
invoke a sense of wellbeing. Tilray’s mission is to be the trusted
partner for its patients and consumers by providing them with a
cultivated experience and health and wellbeing through
high-quality, differentiated brands and innovative products. A
pioneer in cannabis research, cultivation, and distribution,
Tilray’s unprecedented production platform supports over 20 brands
in over 20 countries, including comprehensive cannabis offerings,
hemp-based foods, and alcoholic beverages.
For more information on how we open a world of
wellbeing, visit www.Tilray.com.
Forward-Looking
StatementsCertain statements in this communication that
are not historical facts constitute forward-looking information or
forward-looking statements (together, “forward-looking statements”)
under Canadian securities laws and within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that are intended
to be subject to the “safe harbor” created by those sections and
other applicable laws. Forward-looking statements can be identified
by words such as “forecast,” “future,” “should,” “could,” “enable,”
“potential,” “contemplate,” “believe,” “anticipate,” “estimate,”
“plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and
the negative of these terms or similar expressions, although not
all forward-looking statements contain these identifying words.
Certain material factors, estimates, goals, projections, or
assumptions were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things, the Company’s ability
to commercialize new and innovative products worldwide. Many
factors could cause actual results, performance, or achievement to
be materially different from any forward-looking statements, and
other risks and uncertainties not presently known to the Company or
that the Company deems immaterial could also cause actual results
or events to differ materially from those expressed in the
forward-looking statements contained herein. For a more detailed
discussion of these risks and other factors, see the most recently
filed annual information form of Tilray and the Annual Report on
Form 10-K (and other periodic reports filed with the SEC) of Tilray
made with the SEC and available on EDGAR. The forward-looking
statements included in this communication are made as of the date
of this communication and the Company does not undertake any
obligation to publicly update such forward-looking statements to
reflect new information, subsequent events, or otherwise unless
required by applicable securities laws.
Contacts:
Tilray Global:Jaydon
Casenews@tilray.com
InvestorsRaphael
Gross203-682-8253Raphael.Gross@icrinc.co
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/6056552f-5a26-4b91-a644-f5ce8055f330
Source:
- 1Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ,
Hillman DR, Eastwood PR. Treating insomnia symptoms with medicinal
cannabis: a randomized, crossover trial of the efficacy of a
cannabinoid medicine compared with placebo. Sleep. 2021 Nov 12;44
(11): zsab149. Doi: 10.1093/sleep/zsab149. PMID: 34115851; PMCID:
PMC8598183.
- Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE.
Effects of delta9-tetrahydrocannabinol and cannabinol in man.
Pharmacology. 1975;13(6):502-12. doi: 10.1159/000136944. PMID:
1221432.
Tilray Brands (TSX:TLRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tilray Brands (TSX:TLRY)
Historical Stock Chart
From Apr 2023 to Apr 2024